HaplnScience

COMPANY

HaplnScience, Inc. is a bio-venture company established in late 2018
with the aim to develop fundamental treatments for aging-related diseases.
We will contribute to the health and well-being of humankind by restoring the damaged or
degenerated tissue with aging through research on the unique mechanism of ‘rhHAPLN1’
and its development as a breakthrough anti-aging therapy.

COMPANY

CORE VALUES
Respect

Mutual Respect

Integrity

Honesty
Social Contribution

Openness

Open-minded
Open Communication

CHALLENGE

Passion
Challenge
Responsibility

INNOVATION

New Ideas
New Method
Innovative Value Creation

COMPANY

Milestones
  • 02Participated in the Korean Cartilage Society Conference
  • 03Participated in Bio EU Spring
    Completion of HS-401 DP manufacturing preparation
  • 04HS-601 selected for KDDF project
  • 05Participation in ICPI week
  • 09Participation in Boston RESI
    Participation in China Bio
  • 10Participation in Value Navigator (Shanghai)
    Signed a joint research agreement with SK Plasma
  • 11Participation in Bio EU Fall
    Participation in Invest Korea
    HS-401/402 GLP toxicity studies completed
  • 01Participation in JPM
    Participation in ICSP and company presentation
  • 04Participation in ATST
    Participation in Hanwha Open Innovation
  • 06Participation in Bio USA
    HS-401/402 GLP studies initiated
  • 10Participation in Bio EU Fall
    Participation in Bio Japan
    HS-101 GLP toxicity study initiated
  • 11Participation in China Bio
    Completion of HS-601 PoC
    HS-401 selected for Scale-up TIPS
  • 12Completed the development of HS-401/402 into an inhalation formulation
  • Jan.Participation in JPM (Presentation section)
  • Mar.Participation in Bio Europe spring
    Success of large scale production of HS-401 DS in GMP facility
  • May.HS-201 patent registered in Israel
    Participation in Longevity 2021
  • Jun.Complete PK & Tissue Distribution study of rhHAPLN1
    HS-201 patent registered in Russia
    Participation in Bio Internationial Convention
  • Jul.Manufacturing method patent registered in Korea
  • Oct.HS-201 patent registration allowed in USA/Australia/S.Africa
    Participation in Bio Europe fall
  • Nov.HS-101 patent registration allowed in USA
    Participation in China Healthcare Summit
  • Dec.HS-101 patent registration allowed in EU
    Success of large scale production of HS-401 DS in GMP facility
  • 02Completion of HS-101 OA rat efficacy study
    Initial outcome of HS-101 OA goat efficacy study – Confirmation of cartilage regeneration efficacy
  • 03Initiation of HS-101 DMPK Studies
  • 05Histopathological outcome of HS-101 OA goat efficacy study
  • 06Success of large scale production of recombinant HAPLN1
    Participation in BioDigital 2020
  • 10Initiation of IND enabling efficacy studies of HS-101
    Participation in Bio Europe 2020
    Award of ‘2020 Best Biological Regenerative Medicine Pipeline of the Year’
  • 11Selected as ‘the Top 10 Biotech Startup’ in APAC
  • 12Close of series B funding amounting to 23 billion KRW
  • 01 Investment contract with Blue Point
  • 04Selected as TIPS
    Initiation of the research over rhHAPLN1 manufacturing
  • 05Accreditation as a corporate research institute
  • 07Series A funding amounting to 10 billion KRW
    Initiation of HS-101 OA rat efficacy study
    Initiation of rhHAPLN1 single toxicity study
    Initiation of rhHAPLN1 manufacturing
  • 08Initiation of HS-101 OA goat efficacy study
    Presentation at KBIC 2019
  • 11Participation in Bio Europe 2019
    Presentation at Global Bio Forum
  • 2008Intensive research of anti-aging therapy by Prof. Dae Kyong Kim
  • 2013Identification of HAPLN1’s tissue regenerative function Research on its clinical applications
  • 2016IP application for skin aging therapy
  • 2017Selected as a skin aging therapy project to be supported by MSICT (the Ministry of Science and ICT)
  • 2018.11Foundation of HaplnScience, Inc.
    2018.121billion KRW warranted by KIBO (Korea Technology Finance Corporation)

COMPANY

The team
CEO Hak Bae (Hubert) Choi
Experienced in leading Pharmaceutical companies
  • BS at College of Pharmacy, SNU
  • CEO & President of Korea Kolmar
  • CEO of C&C Research Labs
  • R&D, S&M, Global Business in JW Pharma
CSO Dae Kyong Kim
Expert in Protein Research
  • BS at College of Pharmacy, SNU
  • PhD of Biopharmaceuticals, Graduate School of Pharmacy, University of Tokyo
  • Professor & Dean of College of Pharmacy, Chung-Ang Univsity
  • Head of Social Infra Technology Committee at National Science & Technology Commission
  • Head of Life Welfare Committee of National Science & Technology
Financial Management
CFO Hyun Pil Kang
Head of Finance & Management of Pharmaceutical Company
  • Experienced in financial management of biopharmaceutical companies
  • Experienced in financial planning
  • Directed Management Planning
Development team
In Chul Shin
Development team leader
  • Preclinical development
  • Efficacy, PK/PD, DDS, toxicology studies
  • IND preparation
Business Development team
Chan Young (Jackie) Jang
BD Lead
  • License, Partnership Business strategy
  • New business planning and promotion
  • CEO of SCM Lifescience
  • Chairman of Council for Advanced Regenerative Medicine (CARM)
  • Chairman of CoImmune, Inc. US
  • Vice Chairman of CKD pharm
  • President and CEO of Green Cross Corp./Holdings
  • Post-Doc in University of Wisconsin-Madison
  • PhD of Chemical and Biomedical Engineering, Rice University
  • BS, MS in Seoul National University
Byung-geon Rhee
Non-executive director
  • CEO of Aging Life Sciences
  • Non-executive director, KGII (Korea Genetic Information Institute), QuBest Bio COO of Sangjin trading company
  • BS at College of Pharmacy, Seoul National University
Won Mook Kim
Non-executive director
  • Professional angel investor
  • Planning and sales director, I-sens
  • Head of the Investment Team, Korea Biotech Investment Capital
  • MS of Animal Resource Science, Seoul National University
Gang Se Lee
Non-executive director
  • Managing director, STIC Ventures
  • Technology Strategy Team, Amorepacific
  • Chief researcher, Daishin Securities
  • Chief researcher, Hanhwa Securities
  • Chief researcher, Korea Investment & Securities
  • MS at Biological Science, KAIST
  • BS at Biotechnology, Yonsei University
Bora Chung
Non-executive director
  • Executive director, DSC Investment
  • IMM Investment
  • Hanmi Pharm
  • BS, MS at College of Pharmacy, Seoul National University
Yo-Han Kim
Non-executive director
  • CEO of Lifecore Partners
  • Head of New Business Development, SK Telecom Healthcare
  • Head of Business Development, Seegene
  • Head of Strategic Planning, Seegene
  • BS, MS, Ph.D at College of Engineering, Seoul National University
Sang Kil Lee
Non-executive director
  • CEO of Paijin Science
  • Senior Advisor, 1ST Biotherapeutics
  • Senior Advisor, Handok Pharmaceuticals
  • CEO & Executive Vice President of C&C Research Labs.
  • Senior Principal Scientist, Schering-Plough Research Institute
  • Ph. D. of Pharmaceutical Biochemistry, School of Pharmacy, University of Wisconsin-Madison
Jin Keon Pai
PhD
  • CEO of Biodesigner
  • Professor of Medicine, Ulsan University
  • CEO of the Korea Drug Development Fund
  • Director of the Clinical Research Center, Asan Medical Center
  • Business unit head, Samyang
  • Medical Director, VP of GSK Korea
Dong Ho Lee
PhD, MBA
  • Professor of The Division of Bioscience and Technology at Yonsei University
  • Research Director, Mogam Biotech Research Institute
  • Executive Director, Green Cross Research Center
  • PhD of Biotechnology, Ajou University
  • BS of Microbiology, Seoul National University
Song Yong Park
PhD
  • Chairman of Dept. of Internal Medicine, Konkuk University
  • Associate Professor, Dept. of Internal Medicine, Kangnam St. Mary’s hospital, the Catholic University of Korea
  • Post-Doc, Division of Rheumatology, University of California
  • Director of Planning, Director of Finance, Editorial Chief of Korean College of Rheumatology
  • Consultant Physician, Chief of Rheumatic Disease Section, Human Insurance Reimbursement Agency, Korean Ministry of Health and Welfare
Sang-Heon Lee
MD, PhD
  • Emeritus Professor, Department of Dermatology, Severance Hospital, Yonsei University
  • Director, Medical Science Research Affairs, Yonsei University
  • President, Korean Society for Investigative Dermatology
  • Chairman, Board of Directors, Korean Dermatological Association
  • President, Korean Atopic Dermatitis Association
  • Board of Directors, International Eczema Council
  • Member of National Academy of Medicine of Korea
Kwang Hoon Lee
MD, PhD
  • Professor, Department of Pulmonary and Critical care Medicine, Kangdong Sacred Heart Hospital, Hallym University
  • Associate Professor, Department of Pulmonary and Critical care Medicine, Kangdong Sacred Heart Hospital, Hallym University
  • Fellowship of Pulmonary Critical Care Medicine, Dept. of Medicine, Ulsan University
  • Member of The Asian Pacific Society of Respirology
  • Member of The Korean Academy of Tuberculosis and Respiratory Diseases
  • Member of The Korean Association of Internal Medicine
Yong Bum Park
MD
  • Professor of Rheumatology, Eun Pyeong St. Mary’s Hospital
  • MD, PhD at The Catholic University of Korea
Chonghyeon Yoon
MD, PhD
  • Chief of Dermatology, ASAN Medical Center
  • Associate Professor in Dermatology, UUCM AMC
  • MD at Seoul National University
Chong-hyun Won
MD
  • Associate Professor, Division of Pulmonary and Critical Care Medicine, Samsung Medical Center
  • University of British Columbia-James Hogg R&D Institute
  • MD at Sungkyunkwan University
Hye Yun Park
MD, PhD

COMPANY

PARTNERS